Use of massively parallel pyrosequencing to evaluate the diversity of and selection on plasmodium falciparum csp T-cell epitopes in Lilongwe, Malawi

Journal of Infectious Diseases

Volumn 206, Issue 4, 2012, Pages 580-587

  Bailey, Jeffrey A ^a   Mvalo, Tisungane ^b   Aragam, Nagesh ^c   Weiser, Matthew ^d   Congdon, Seth ^c   Kamwendo, Debbie ^b   Martinson, Francis ^b   Hoffman, Irving ^c   Meshnick, Steven R ^d   Juliano, Jonathan J ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; EPITOPE; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; PROTOZOAL DNA; PROTOZOAL PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHILD; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC DISTANCE; GENETIC SELECTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALAWI; MALE; MASSIVE PARALLEL PYROSEQUENCING; NONHUMAN; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; POPULATION GENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PYROSEQUENCING; UNINDEXED SEQUENCE; VACCINATION; CHEMISTRY; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MALARIA FALCIPARUM; MIDDLE AGED; MOLECULAR GENETICS; PARASITOLOGY; PLASMODIUM FALCIPARUM;

ADULT; CHILD, PRESCHOOL; DNA, PROTOZOAN; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VARIATION; HAPLOTYPES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT; MALARIA, FALCIPARUM; MALAWI; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84866943868     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis329     Document Type: Article

References (43)

1. Das P, Horton R. Malaria elimination: worthy, challenging, and just possible. Lancet 2010; 376:1515-7.
2. Feachem RG, Phillips AA, Targett GA, Snow RW. Call to action: priorities for malaria elimination. Lancet 2010; 376:1517-21.
3. World Health Organization (WHO). World malaria report: 2010. WHO: Geneva, Switzerland, 2010.
4. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol 2009; 31:560-73.
5. Juliano JJ, Porter K, Mwapasa V, et al. Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing. Proc Natl Acad Sci U S A 2010; 107:20138-43.
6. Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011; 365:1004-13.
7. Takala SL, Coulibaly D, Thera MA, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 2009; 1:2ra5.
8. The RTS SCTP. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 20:1863-75.
9. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010; 6:90-6.
10. Kappe SH, Buscaglia CA, Nussenzweig V. Plasmodium sporozoite molecular cell biology. Annu Rev Cell Dev Biol 2004; 20:29-59.
11. Lockyer MJ, Marsh K, Newbold CI. Wild isolates of Plasmodium falciparum show extensive polymorphism in T cell epitopes of the circumsporozoite protein. Mol Biochem Parasitol 1989; 37:275-80.
12. Good MF, Berzofsky JA, Miller LH. The T cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development. Annu Rev Immunol 1988; 6:663-88.
13. Waitumbi JN, Anyona SB, Hunja CW, et al. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One 2009; 4:e7849.
14. Jalloh A, van Thien H, Ferreira MU, et al. Sequence variation in the T-cell epitopes of the Plasmodium falciparum circumsporozoite protein among field isolates is temporally stable: a 5-year longitudinal study in southern Vietnam. J Clin Microbiol 2006; 44:1229-35.
15. Alloueche A, Milligan P, Conway DJ, et al. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg 2003; 68:97-101.
16. Hughes AL. Circumsporozoite protein genes of malaria parasites (Plasmodium spp.): evidence for positive selection on immunogenic regions. Genetics 1991; 127:345-53.
17. Jongwutiwes S, Tanabe K, Hughes MK, Kanbara H, Hughes AL. Allelic variation in the circumsporozoite protein of Plasmodium falciparum from Thai field isolates. Am J Trop Med Hyg 1994; 51:659-68.
18. Weedall GD, Preston BM, Thomas AW, Sutherland CJ, Conway DJ. Differential evidence of natural selection on two leading sporozoite stage malaria vaccine candidate antigens. Int J Parasitol 2007; 37:77-85.
19. Alloueche A, Silveira H, Conway DJ, et al. High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein. Mol Biochem Parasitol 2000; 106:273-82.
20. Zagordi O, Bhattacharya A, Eriksson N, Beerenwinkel N. ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data. BMC Bioinformatics 2011; 12:119.
21. Colwell RK. EstimateS: statistical estimation of species richness and shared species from samples. 2011. http://viceroy.eeb.uconn.edu/ estimates. Accessed 17 September 2011.
22. Librado P, Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics 2009; 25:1451-2.
23. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 2010; 10:564-7.
24. Bandelt HJ, Forster P, Rohl A. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol 1999; 16:37-48.
25. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drugresistant viral variants in chronically HIV-infected, antiretroviral treatment- naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199:693-701.
26. Chao A. Estimating the population size for capture-recapture data with unequal catchability. Biometrics 1987; 43:783-91.
27. Hawkins VN, Auliff A, Prajapati SK, et al. Multiple origins of resistance- conferring mutations in Plasmodium vivax dihydrofolate reductase. Malar J 2008; 7:72.
28. Tajima F. Evolutionary relationship of DNA sequences in finite populations. Genetics 1983; 105:437-60.
29. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 1989; 123:585-95.
30. Zouros E. Mutation rates, population sizes and amounts of electrophoretic variation of enzyme loci in natural populations. Genetics 1979; 92:623-46.
31. Tajima F. Measurement of DNA polymorphism. In: Takahata N, Clark AG, eds. Introduction to molecular paleopopulation biology. Tokyo: Japan Scientific Societies Press, 1993:37-59.
32. Hoffmann C, Minkah N, Leipzig J, et al. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res 2007; 35:e91.
33. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007; 17:1195-201.
34. Rozera G, Abbate I, Bruselles A, et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009; 6:15.
35. Mitsuya Y, Varghese V, Wang C, et al. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol 2008; 82:10747-55.
36. Archer J, Braverman MS, Taillon BE, et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009; 23:1209-18.
37. Kumkhaek C, Phra-Ek K, Renia L, et al. Are extensive T cell epitope polymorphisms in the Plasmodium falciparum circumsporozoite antigen, a leading sporozoite vaccine candidate, selected by immune pressure? J Immunol 2005; 175:3935-9.
38. Jalloh A, Jalloh M, Matsuoka H. T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: age-dependent haplotype distribution? Malar J 2009; 8:120.
39. Spurgin LG, Richardson DS. How pathogens drive genetic diversity: MHC, mechanisms and misunderstandings. Proc Biol Sci 2010; 277:979-88.
40. Martcheva M, Bolker BM, Holt RD. Vaccine-induced pathogen strain replacement: what are the mechanisms? J R Soc Interface 2008; 5:3-13.
41. Gandon S, Day T. The evolutionary epidemiology of vaccination. J R Soc Interface 2007; 4:803-17.
42. Iannelli M, Martcheva M, Li XZ. Strain replacement in an epidemic model with super-infection and perfect vaccination. Math Biosci 2005; 195:23-46.
43. Enosse S, Dobano C, Quelhas D, et al. RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials 2006; 1:e5.